Electrochemical-Induced Solvent-tuned Selective Transfer

Hydrogenation of Imidazopyridines with Carbazates as Hydrogen

Donor

Zhicong Tang, Gang Hong, Jian Chen, Ting Huang, Zichao Zhou and Limin Wang* * Key Laboratory for Advanced Materials and Institute of Fine Chemicals, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, P. R. China. Fax & Tel: +86-21-64253881. Email: wanglimin@ecust.edu.cn

Contents

1.	General Information	S2
2.	Optimization of The Reaction Conditions	S3
3.	General Experimental Procedures	S4
4.	General procedure for the synthesis of compound 6 ^[1]	S6
5.	General procedure for the synthesis of compound 8 ^[2-3]	S6
6.	Exploration of solvent effect	S7
7.	Cyclic voltammetry studies	S7
8.	Characterization Data of Products	S9
9.	References	S21
10.	Copies of 1H NMR, 13C NMR and 19F NMR	S22

1. General Information

All reactions were carried out under Ar unless otherwise noted. Commercial reagents were used as received without additional purification unless otherwise noted. Substituted imidazopyridines were prepared according to the literature procedure.¹ Reactions were monitored by thin layer chromatography (TLC) using Silicycle glass-backed TLC plates with 250 µm silica and F254 indicator. Visualization was accomplished by UV light.

¹H NMR, ¹³C NMR, and ¹⁹F NMR spectra were recorded on a AM-500 Fourier transform NMR spectrometer at 400/600 MHz, 125/151 MHz, 376 MHz respectively. Chemical shifts are reported relative to the solvent resonance peak δ 2.50 (DMSO-d₆) for ¹H; δ 39.52 (DMSO-d₆) or 77.16 (CDCl₃) for ¹³C. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b = broad singlet, m = multiplet), coupling constants, and number of protons. High resolution mass spectra were obtained using a VG autospec with an ionization mode of EI-TOF. Infrared spectra are reported in cm⁻¹. Column chromatography was performed with silica gel (50-63 µm mesh particle size).

2. Optimization of The Reaction Conditions

Table S1. Optimization of Transfer Hydrogenation for 3a^a

	N → + H ₂ N		C cloth(+ <u>ⁿBu₄N</u> 70 °)Pt(-), I=15 m. <u>IBF₄, MeCN</u> C, 12 h, Ar	A,	N N
	1a	2a	und	ivided cell	3	а
Entry	Electrode	Electrolyte	Solvent	Temp./°C	Yield ^b of 3a [%]	Yield ^b of 4a [%]
1	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	82	trace
2	C cloth(+) Pt(-)	ⁿ Bu ₄ NClO ₄	MeCN	70	N. D.	N. D.
3	C cloth(+) Pt(-)	ⁿ Bu ₄ NBr	MeCN	70	N. D.	N. D.
4	C cloth(+) Pt(-)	ⁿ Bu ₄ NPF ₆	MeCN	70	72	trace
5	Pt(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	68	trace
6	C cloth(+) Ni(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	75	10
7	GC(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	trace	trace
8	C cloth(+) C cloth(-)	$^{n}Bu_{4}NBF_{4}$	MeCN	70	60	14
9	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	DMSO	70	8	72
10	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	THF	70	N. D.	N. D.
11	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	DCE	70	N. D.	N. D.
12	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	DMF	70	N. D.	N. D.
13	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	H_2O	70	N. D.	N. D.
14 ^c	C cloth(+) Pt(-)	$^{n}\mathrm{Bu}_{4}\mathrm{NBF}_{4}$	MeCN	70	65	18
15^{d}	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	70	13
16	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	r. t.	33	trace
17	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	90	67	22
18^{e}	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	trace	trace
19 ^f	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	MeCN	70	N. D.	N. D.
20 ^g	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	MeCN	70	N. D.	N. D.

^{*a*} Standard conditions: undivided cell, carbon cloth anode $(10 \times 10 \text{ mm})$, Pt cathode $(10 \times 10 \times 0.1 \text{ mm})$, **1a** (0.5 mmol), **2a** (2.5 mmol), ⁿBu₄NBF₄ (0.1 M), MeCN (10 mL), CCE = 15 mA, 12 h, 70 °C, under Ar. ^{*b*} Isolated yields. ^{*c*} CCE = 10 mA, 18 h. ^{*d*} CCE = 20 mA, 8 h. ^{*e*} Under air. ^{*f*} No electric current. ^{*g*} Without carbazate **2a**.

N-	N + H ₂ NH		C cloth <u>ⁿBu,</u> 70 ur	(+)Pt(-), I=1 <u>₄NBF₄, DM</u> ⁰C, 12 h, A ndivided cel	8 mA, SO Ar	
	1a	2a				4d
Entry	Electrode	Electrolyte	I/mA	Time/h	Yield ^b of 3a [%]	Yield ^b of 4a [%]
1	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	18	12	trace	80
2	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	20	12	trace	76
3	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	18	18	trace	85
4	C cloth(+) Pt(-)	ⁿ Bu ₄ NBF ₄	18	24	trace	81
5	Pt(+) Pt(-)	ⁿ Bu ₄ NBF ₄	18	18	11	69
6	Pt(+) Ni(-)	ⁿ Bu ₄ NBF ₄	18	18	trace	80
7	GC(+) Pt(-)	ⁿ Bu ₄ NBF ₄	18	18	trace	trace
8	C cloth(+) C cloth(-)	ⁿ Bu ₄ NBF ₄	18	18	trace	66
9	C cloth(+) Pt(-)	ⁿ Bu ₄ NClO ₄	18	18	trace	trace
10	C cloth(+) Pt(-)	ⁿ Bu ₄ NBr	18	18	trace	trace
11	C cloth(+) Pt(-)	ⁿ Bu ₄ NPF ₆	18	18	trace	78
12 ^c	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	18	18	trace	trace
13	C cloth(+) Pt(-)	$^{n}Bu_{4}NBF_{4}$	0	18	N. D.	N. D.
14 ^d	$C \operatorname{cloth}(+) \operatorname{Pt}(-) $	ⁿ Bu ₄ NBF ₄	18	18	N. D.	N. D.

Table S2. Optimization of Transfer Hydrogenation for 4a^a

^{*a*} Reaction conditions: undivided cell, carbon cloth anode $(10 \times 10 \text{ mm})$, Pt cathode $(10 \times 10 \times 0.1 \text{ mm})$, Ni foam cathode $(10 \times 10 \text{ mm})$, Glassy carbon anode $(10 \times 10 \times 1 \text{ mm})$, **1a** (0.5 mmol), **2a** (2.5 mmol), ⁿBu₄NBF₄ (0.1 M), DMSO (10 mL), CCE = 15 mA, 12 h, 70 °C, under Ar. ^{*b*} Isolated yields. ^{*c*} Under air. ^{*d*} Without carbazate **2a**.

3. General Experimental Procedures



General Procedure A – for the preparation of products 3:

Imidazo[1,2-*a*]pyridine (1, 0.5 mmol), *tert*-butyl carbazate (**2a**, 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) were added to a three-necked, roundbottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. After completion, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The reaction mixture was purified by column chromatography over silica gel eluting with petroleum ether/dichloromethane to give the desired products **3**.

General Procedure B - for the preparation of products 4:



Imidazo[1,2-*a*]pyridine (1, 0.5 mmol), *tert*-butyl carbazate (**2a**, 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) were added to a three-necked, roundbottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. After completion, the reaction mixture was washed with water and extracted with CH₂Cl₂ (10 mL x 3). The organic layers were combined, dried over Na₂SO₄, and concentrated. The reaction mixture was purified by column chromatography over silica gel eluting with petroleum ether/dichloromethane to give the desired products **4**.

General Procedure C - for gram scale preparation of 3a and 4a:



Imidazo[1,2-*a*]pyridine **1a** (5 mmol, 0.97 g), *tert*-butyl carbazate **2a** (25 mmol, 3.30 g), ⁿBu₄NBF₄ (2.5 mmol, 823.2 mg) were added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The reaction was carried out with 15 mA current using MeCN as solvent or 18 mA current using DMSO as solvent for 48 h at 70 °C under argon. After completion, the reaction mixture was washed with water and extracted with CH₂Cl₂ (10 mL x 3). The organic layers were combined, dried over Na₂SO₄, and concentrated. The reaction mixture was purified by column chromatography over silica gel eluting with petroleum ether/dichloromethane to give the desired products **3a** (64%, 623 mg)

under condition A and 4a (72%, 714 mg) under condition B.

4. General procedure for the synthesis of compound 6^[1]



The hydrogenation product **4r** was obtained from **1r** in 78% yield by general procedure **C**. A solution of **4r** (1.0 mmol), sodium sulfinate (1.5 mmol), and LiClO₄ (320 mg, 0.42 M) in a mixture of CH₃CN and H₂O (14 mL, v/v = 2.5:1) was added to the undivided cell equipped with a carbon anode and a platinum cathode. The reaction mixture was stirred and electrolyzed at a constant current of 7 mA under room temperature for 15 h. After the reaction was complete, the residue was diluted with EtOAc (10 mL), washed with water, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography to afford the desired product **6**.

5. General procedure for the synthesis of compound 8^[2-3]



To an oven dried 12 mL scintillation vial equipped with a magnetic stir bar, the compound **4r** (0.6 mmol, 1.0 equiv), *N*-iodosuccinimide (0.6 mmol, 1.0 equiv), *p*-toluenesulfonic acid (0.6 mmol, 1.0 equiv) were dissolved in the CH₃CN (6 mL, 0.1 M). The reaction mixture was stirred at ambient temperature for 4 h under argon atmosphere. After the reaction was complete by TLC, it was quenched with sat. Na₂S₂O₃ (10 mL), neutralized with sat. NaHCO₃ and extracted with DCM (20 mL × 3). The combined organic layers were washed with sat. NaHCO₃ (20 mL), followed by brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography using EA/DCM as an eluent to provide the desired product 7 (181.8 mg, 81%). Compound 7 (150.0 mg, 0.4 mmol), Pd (PPh₃)₂Cl₂ (28 mg, 0.04 mmol, 10%) and CuI (8 mg, 0.05 mmol, 10%) were introduced into a screwcap test tube. The tube was sealed with a rubber septum and then evacuated and refilled with argon thrice. DMF (2 mL),

Et₃N (225 μ L, 1.6 mmol, 4 eq.) and phenylacetylene (44.9 mg, 0.44 mmol, 1.1 eq.)

were then added. The reaction mixture was stirred for 1.5 h at 80 °C. After cooling down to room temperature, the reaction mixture was partitioned between CH_2Cl_2 (10 mL) and brine (10 mL). The aqueous phase was extracted twice with CH_2Cl_2 (10 mL). Organic phases were reunited, dried over MgSO₄ and evaporated to dryness. The crude mixture was purified by silica gel column chromatography (EtOAc/petroleum ether = 1:5) to afford compound **8** as a white solid (133.8 mg, 78% overall yield).

6. Deuterium-labelling experiments



To an oven dried 25 mL scintillation vial equipped with a magnetic stir bar, the compound **2a** (10 mmol, 1.32 g) were dissolved in DMSO- d_6 (10 mL). The reaction mixture was stirred at 60 °C for 12 h under argon atmosphere for hydrogen-deuterium exchange. After the reaction was complete, it was washed by brine (20 mL) and extracted with EA (20 mL × 3), followed by dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to provide the deuterated carbazate **2aa** (1.03 g, 78%).





Imidazo[1,2-*a*]pyridine (**1a**, 0.5 mmol), deuterated *tert*-butyl carbazate (**2aa**, 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) were added to a threenecked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. **4aa** was isolated in 78% yield by column chromatography with 49-64% D-incorporation as revealed by ¹H NMR.

7. Exploration of solvent effect

Table S3. Exploration of solvent effect^a



Destary	Solvent retio	Yie	Yield%		
Entry	Solvent Fatio	3 a	4a		
1	MeCN (10 mL)	80	trace		
2	MeCN:DMSO=9:1	74	16		
3	MeCN:DMSO=7:3	56	35		
4	MeCN:DMSO=5:5	41	46		
5	MeCN:DMSO=3:7	15	72		
6	MeCN:DMSO=1:9	9	80		
7	DMSO (10 mL)	trace	84		

^{*a*} Standard conditions: **1a** (0.5 mmol), **2a** (2.5 mmol), undivided cell, carbon cloth anode (10×10 mm), Pt cathode ($10 \times 10 \times 0.1$ mm), CCE = 18 mA, ⁿBu₄NBF₄ (0.1 M), solvent (10 mL), 18 h, 70 °C, under Ar. ^{*b*} Isolated yields

8. Cyclic voltammetry studies

The cyclic voltammograms were recorded in 0.1 M $^{n}Bu_4NBF_4$ solution in MeCN/DMSO with glassy carbon as the working electrode, Pt wire as the counter electrode and an Ag/AgCl (KCl sat'd) reference electrode as a reference electrode at room temperature. The scan rate was 100 mV/s. The reduction peak potential of 2-phenylimidazo[1,2-*a*]pyridine **1a** was observed at $E_p = -1.33 \sim -1.05$ V vs. Ag/AgCl.



Figure S1. The cyclic voltammetry test of 1a with different ratio of MeCN/DMSO.

9. Characterization Data of Products

2-phenyl-5,6-dihydroimidazo[1,2-a]pyridine (3a)



General procedure A was followed using **1a** (97.0 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3a** in 82% yield (80.4 mg) as a yellow solid: ¹H NMR (600 MHz, Chloroform-*d*) δ 7.80 – 7.73 (m, 2H), 7.41 – 7.33 (m, 2H), 7.25 – 7.19 (m, 1H), 7.14 (s, 1H), 6.09 – 6.02 (m, 1H), 5.94 – 5.86 (m, 1H), 4.84 – 4.49 (m, 2H), 3.85 – 3.40 (m, 2H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₃N₂ 197.1079, found 197.0986. Spectral data match those previously reported.^[4]

7-methyl-2-phenyl-5,6-dihydroimidazo[1,2-a]pyridine (3b)



General procedure A was followed using 1b (104.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3b in 85% yield (89.3 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.84 – 7.64 (m, 2H), 7.36 (t, *J* = 7.7 Hz, 2H), 7.26 – 7.20 (m, 1H), 7.15 (s, 1H), 5.81 – 5.46 (m, 1H), 4.71 – 4.46 (m, 2H), 3.44 (t, *J* = 5.0 Hz, 2H), 1.90 (d, *J* = 2.1 Hz, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₅N₂ 211.1235, found 211.1226. Spectral data match those previously reported.^[4]

6-methyl-2-phenyl-7,8-dihydroimidazo[1,2-a]pyridine (3c)



General procedure A was followed using 1c (104.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3c in 75% yield (78.8 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.91 – 7.63 (m, 2H), 7.36 (dd, J = 8.4, 7.1 Hz, 2H), 7.25 – 7.19

(m, 1H), 7.12 (s, 1H), 5.78 - 5.60 (m, 1H), 4.50 - 4.30 (m, 2H), 3.61 - 3.43 (m, 2H), 1.93 - 1.74 (m, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₅N₂ 211.1235, found 211.1222. Spectral data match those previously reported.^[4]

6-fluoro-2-phenyl-7,8-dihydroimidazo[1,2-a]pyridine (3e)

General procedure A was followed using 1e (106.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3e in 58% yield (62.1 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 8.02 – 7.63 (m, 2H), 7.37 (dd, *J* = 8.4, 6.9 Hz, 2H), 7.26 – 7.21 (m, 1H), 7.14 (s, 1H), 5.94 – 5.49 (m, 1H), 4.98 – 4.50 (m, 2H), 3.81 – 3.48 (m, 2H).HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₂N₂F 215.0985, found 215.0975. Spectral data match those previously reported.^[4]

2-(4-fluorophenyl)-5,6-dihydroimidazo[1,2-a]pyridine (3f)



General procedure A was followed using 1f (106.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3f in 64% yield (68.5 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.84 – 7.54 (m, 2H), 7.07 (s, 1H), 7.07 – 6.89 (m, 2H), 6.18 – 5.97 (m, 1H), 5.97 – 5.84 (m, 1H), 4.72 – 4.43 (m, 2H), 3.67 – 3.42 (m, 2H).HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₂N₂F 215.0985, found 215.0980. Spectral data match those previously reported.^[4]

2-(p-tolyl)-5,6-dihydroimidazo[1,2-a]pyridine (3j)



General procedure A was followed using 1j (104.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3j in 79% yield (83.0 mg) as a yellow solid: ¹H NMR (400

MHz, Chloroform-*d*) δ 7.96 – 7.54 (m, 2H), 7.17 (d, *J* = 7.9 Hz, 2H), 7.09 (s, 1H), 6.15 – 5.97 (m, 1H), 5.93 – 5.70 (m, 1H), 4.70 – 4.44 (m, 2H), 3.87 – 3.44 (m, 2H), 2.35 (s, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₅N₂ 211.1235, found 211.1233. Spectral data match those previously reported.^[4]

2-(o-tolyl)-5,6-dihydroimidazo[1,2-a]pyridine (3k)



General procedure A was followed using **1k** (104.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode ($10 \times 10 \text{ mm}$) and platinum plate cathode ($10 \times 10 \times 0.1 \text{ mm}$). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3k** in 82% yield (86.1 mg) as a yellow solid (mp 141-143 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 7.74 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.17 – 7.04 (m, 3H), 6.88 (s, 1H), 6.22 – 5.88 (m, 1H), 5.86 – 5.77 (m, 1H), 4.72 – 4.23 (m, 2H), 3.77 – 3.35 (m, 2H), 2.38 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 141.58, 140.24, 134.74, 133.65, 130.68, 128.45, 126.66, 125.93, 123.18, 119.76, 115.83, 44.98, 25.05, 21.84. IR (film) 3441, 3317, 2975, 1702, 1642, 1480, 1388, 1365, 1248, 1152, 1048, 1017, 933, 848, 786, 732, 701, 601, 509 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₅N₂ 211.1235, found 211.1227.

2-(4-methoxyphenyl)-5,6-dihydroimidazo[1,2-a]pyridine (3l)



General procedure A was followed using **11** (112.0 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **31** in 80% yield (90.4 mg) as a yellow solid (mp 102-104 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 7.88 – 7.50 (m, 2H), 7.04 (s, 1H), 6.97 – 6.82 (m, 2H), 6.14 – 5.98 (m, 1H), 5.95 – 5.81 (m, 1H), 4.74 – 4.53 (m, 2H), 3.82 (s, 3H), 3.63 – 3.49 (m, 2H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 158.66, 142.29, 141.10, 127.29, 123.13, 119.83, 114.04, 112.15, 55.35, 45.01, 25.18. IR (film) 3389, 3133, 3039, 2961, 2908, 2837, 1905, 1707, 1660, 1558, 1519, 1479, 1443, 1296, 1247, 1178, 1057, 1033, 979, 948, 840, 755, 669, 637, 539 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₅N₂O 227.1184, found 227.1175.

2-(4-(tert-butyl)phenyl)-5,6-dihydroimidazo[1,2-a]pyridine (3m)



General procedure A was followed using **1m** (125.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3m** in 89% yield (112.2 mg) as a yellow solid (mp 121-123 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 7.79 – 7.61 (m, 2H), 7.50 – 7.33 (m, 2H), 7.11 (s, 1H), 6.34 – 5.94 (m, 1H), 5.94 – 5.56 (m, 1H), 4.76 – 4.40 (m, 2H), 3.78 – 3.44 (m, 2H), 1.33 (s, 9H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 149.73, 142.42, 141.32, 131.55, 125.57, 124.66, 123.27, 119.82, 112.85, 45.10, 34.65, 31.49, 25.24. IR (film) 3135, 3039, 2961, 2904, 2867, 1905, 1710, 1611, 1519, 1478, 1426, 1396, 1265, 1195, 1163, 956, 841, 756, 725, 663, 555 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₇H₂₁N₂ 253.1705, found 253.1697.

7-methyl-2-(p-tolyl)-5,6-dihydroimidazo[1,2-a]pyridine (3n)



General procedure A was followed using 1n (111.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3n in 79% yield (88.6 mg) as a yellow solid: ¹H NMR (600 MHz, Chloroform-*d*) δ 7.77 – 7.51 (m, 2H), 7.17 (d, *J* = 7.9 Hz, 2H), 7.09 (s, 1H), 5.62 – 5.56 (m, 1H), 4.60 – 4.47 (m, 2H), 3.42 (t, *J* = 5.3 Hz, 2H), 2.35 (s, 3H), 1.90 (d, *J* = 2.3 Hz, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₅H₁₇N₂ 255.1392, found 255.1381. Spectral data match those previously reported.^[4]

2-(4-ethylphenyl)-6-methyl-7,8-dihydroimidazo[1,2-a]pyridine (30)



General procedure A was followed using **1o** (118.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3o** in 67% yield (79.8 mg) as a yellow solid (mp 109-111 °C): ¹H NMR (600 MHz, Chloroform-*d*) δ 7.68 (d, *J* = 8.1 Hz, 2H), 7.19 (d, *J* = 7.9 Hz,

2H), 7.08 (s, 1H), 5.89 – 5.53 (m, 1H), 4.44 (t, J = 5.1 Hz, 2H), 3.60 – 3.37 (m, 2H), 2.65 (q, J = 7.6 Hz, 2H), 1.85 (d, J = 2.5 Hz, 3H), 1.25 (t, J = 7.6 Hz, 3H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 142.84, 142.67, 141.51, 131.83, 128.16, 127.15, 124.92, 117.86, 112.45, 48.57, 28.72, 25.20, 20.44, 15.68. IR (film) 3419, 2963, 2877, 1619, 1558, 1526, 1488, 1433, 1381, 1342, 1058, 883, 837, 795, 764, 740, 530 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₆H₁₉N₂ 239.1548, found 239.1540.

2-(4-methoxyphenyl)-7-methyl-5,6-dihydroimidazo[1,2-a]pyridine (3p)



General procedure A was followed using **1p** (119.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3p** in 88% yield (105.7 mg) as a yellow solid (mp 130-132 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.06 – 7.53 (m, 2H), 7.04 (s, 1H), 6.94 – 6.85 (m, 2H), 5.64 – 5.49 (m, 1H), 4.81 – 4.45 (m, 2H), 3.82 (s, 3H), 3.46 – 3.34 (m, 2H), 2.09 – 1.67 (m, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 158.71, 143.04, 141.19, 131.16, 127.21, 126.15, 114.22, 114.09, 112.10, 55.40, 45.04, 29.70, 23.02. IR (film) 2959, 2875, 1708, 1609, 1511, 1481, 1372, 1244, 1172, 1052, 1027, 956, 834, 732, 701, 601, 523 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₅H₁₇N₂O 241.1341, found 241.1339.

2-([1,1'-biphenyl]-4-yl)-5,6-dihydroimidazo[1,2-a]pyridine (3q)



General procedure A was followed using 1q (135.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded 3q in 85% yield (115.7 mg) as a yellow solid (mp 154-156 °C): ¹H NMR (600 MHz, Chloroform-*d*) δ 7.91 – 7.74 (m, 2H), 7.67 – 7.60 (m, 4H), 7.43 (t, *J* = 7.7 Hz, 2H), 7.37 – 7.27 (m, 1H), 7.19 (s, 1H), 6.14 – 6.01 (m, 1H), 5.96 – 5.90 (m, 1H), 4.68 – 4.57 (m, 2H), 3.64 – 3.54 (m, 2H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 142.73, 141.10, 140.91, 139.50, 133.35, 128.87, 127.40, 127.22, 127.03, 125.30, 119.80, 113.39, 45.18, 25.25. IR (film) 3386, 3038, 2962, 2900, 1913, 1667, 1596, 1612, 1558, 1488, 1450, 1427, 1396, 1373, 1326, 1191, 1157, 1080, 1002, 948, 894, 847, 756, 725, 694, 663, 486 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₉H₁₇N₂ 273.1392, found 273.1384.

2-(naphthalen-2-yl)-5,6-dihydroimidazo[1,2-a]pyridine (3r)



General procedure A was followed using **1r** (122.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and MeCN (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (15 mA) electrolysis was carried out at 70 °C under argon for 12 h. Chromatography (DCM/EA = 50/1) afforded **3r** in 83% yield (102.2 mg) as a yellow solid (mp 144-146 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.30 (s, 1H), 7.87 (dd, *J* = 7.6, 1.6 Hz, 1H), 7.84 – 7.78 (m, 4H), 7.50 – 7.36 (m, 2H), 6.16 – 5.98 (m, 1H), 5.99 – 5.85 (m, 1H), 4.83 – 4.51 (m, 2H), 3.70 – 3.48 (m, 2H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 142.79, 141.08, 133.89, 132.60, 131.51, 128.12, 127.65, 126.11, 125.34, 123.64, 123.09, 122.79, 119.69, 113.70, 45.07, 25.15. IR (film) 3131, 3046, 2897, 1928, 1837, 1710, 1666, 1599, 1518, 1419, 1396, 1372, 1318, 1186, 1163, 995, 923, 863, 770, 728, 669, 640, 594, 476 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₇H₁₅N₂ 247.1235, found 247.1225.

2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4a)



General procedure B was followed using **1a** (97.0 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4a** in 85% yield (84.2 mg) as a yellow solid: ¹H NMR (600 MHz, Chloroform-*d*) δ 7.83 – 7.56 (m, 2H), 7.45 (s, 1H), 7.31 (t, *J* = 7.7 Hz, 2H), 7.24 – 7.05 (m, 1H), 3.95 (t, *J* = 5.9 Hz, 2H), 2.75 (t, *J* = 6.3 Hz, 2H), 2.04 – 1.88 (m, 2H), 1.88 – 1.82 (m, 2H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₅N₂ 199.1235, found 199.1238. Spectral data match those previously reported.^[5]

7-methyl-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4b)



General procedure B was followed using **1b** (104.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography

(DCM/EA = 8/1) afforded **4b** in 78% yield (82.8 mg) as a yellow oil: ¹H NMR (400 MHz, DMSO- d_6) δ 7.97 – 7.61 (m, 2H), 7.45 (s, 1H), 7.31 (t, *J* = 7.8 Hz, 2H), 7.22 – 7.10 (m, 1H), 4.17 – 3.79 (m, 2H), 3.00 – 2.80 (m, 1H), 2.39 – 2.25 (m, 1H), 2.13 – 1.89 (m, 2H), 1.74 – 1.51 (m, 1H), 1.07 (d, *J* = 6.5 Hz, 3H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 145.43, 140.52, 134.34, 128.66, 126.69, 124.87, 114.01, 45.03, 24.65, 23.16, 21.23. IR (film) 3116, 3067, 2975, 2940, 1719, 1643, 1504, 1473, 1365, 1303, 1245, 1080, 1065, 919, 864, 786, 724, 694 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₇N₂ 213.1392, found 213.1379.

6-methyl-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4c)



General procedure B was followed using **1c** (104.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4c** in 70% yield (74.3 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.81 – 7.66 (m, 2H), 7.34 (dd, J = 8.4, 7.0 Hz, 2H), 7.24 – 7.15 (m, 1H), 7.04 (s, 1H), 4.14 – 3.96 (m, 1H), 3.52 (dd, J = 12.1, 10.2 Hz, 1H), 3.07 (d, J = 17.1, 3.2 Hz, 1H), 2.93 – 2.77 (m, 1H), 2.22 – 1.97 (m, 2H), 1.69 – 1.50 (m, 1H), 1.12 (d, J = 6.7 Hz, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₇N₂ 213.1392, found 213.1382. Spectral data match those previously reported.^[2]

8-methyl-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4d)



General procedure B was followed using **1d** (104.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4d** in 59% yield (62.6 mg) as a yellow oil: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.74 (dd, *J* = 8.1, 1.5 Hz, 2H), 7.34 (t, *J* = 7.7 Hz, 2H), 7.21 – 7.15 (m, 1H), 7.01 (s, 1H), 4.16 – 3.75 (m, 2H), 3.13 – 2.77 (m, 1H), 2.13 – 2.00 (m, 2H), 1.96 – 1.84 (m, 1H), 1.60 – 1.51 (m, 1H), 1.45 (d, *J* = 6.9 Hz, 3H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 149.86, 140.61, 134.69, 128.50, 126.40, 124.87, 113.87, 45.13, 30.26, 29.82, 21.65, 19.97; IR (film) 2938, 2864, 1718, 1640, 1511, 1473, 1452, 1380, 1318, 1257, 1118, 1072, 1026, 948, 909, 856, 727, 694, 641, 506 cm⁻¹; HRMS (ESI-TOF) calcd for ([C₁₄H₁₇N₂]⁺) [M+H]⁺ m/z = 213.1392; found 213.1379.

2-(4-fluorophenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4f)



General procedure B was followed using 1f (106.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded 4f in 73% yield (78.9 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.92 – 7.53 (m, 2H), 7.34 (t, *J* = 7.7 Hz, 1H), 7.24 – 7.16 (m, 1H), 7.04 (d, *J* = 12.8 Hz, 1H), 3.96 (dd, *J* = 7.3, 4.3 Hz, 2H), 2.96 – 2.87 (m, 2H), 2.06 – 1.85 (m, 4H).HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₃H₁₄N₂F 217.1141, found 217.1148. Spectral data match those previously reported.^[5]

2-(p-tolyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4j)



General procedure B was followed using **1j** (104.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4j** in 88% yield (93.4 mg) as a yellow solid: ¹H NMR (400 MHz, Chloroform-*d*) δ 7.80 – 7.48 (m, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 7.02 (d, *J* = 1.1 Hz, 1H), 3.96 (t, *J* = 5.8 Hz, 2H), 2.92 (t, *J* = 6.1 Hz, 2H), 2.34 (s, 3H), 2.11 – 1.84 (m, 4H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 145.26, 140.52, 136.32, 131.46, 129.35, 124.80, 113.54, 44.97, 24.58, 23.14, 21.31, 21.19.; IR (film) 2945, 2896, 1714, 1640, 1558, 1509, 1481, 1430, 1383, 1309, 1258, 1186, 1109, 1074, 910, 834, 727, 646, 550 cm⁻¹; HRMS (ESI-TOF) calcd for ([C₁₄H₁₇N₂]⁺) [M+H]⁺ m/z = 213.1392; found 213.1385.

2-(o-tolyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4k)



General procedure B was followed using 1k (104.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded 4k in 79% yield (83.8 mg) as a yellow solid:¹H NMR (400

MHz, Chloroform-*d*) δ 7.83 (dd, J = 7.7, 1.4 Hz, 1H), 7.30 – 7.04 (m, 3H), 6.90 (s, 1H), 3.99 (t, J = 5.8 Hz, 2H), 2.93 (t, J = 6.3 Hz, 2H), 2.46 (s, 3H), 2.19 – 1.88 (m, 4H). HRMS (ESI-TOF) calcd for ([C₁₄H₁₇N₂]⁺) [M+H]⁺ m/z = 213.1392; found 213.1386. Spectral data match those previously reported.^[5]

2-(4-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (41)



General procedure B was followed using **11** (97.0 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4I** in 68% yield (77.6 mg) as a yellow solid:¹H NMR (400 MHz, Chloroform-*d*) δ 8.22 – 7.41 (m, 2H), 6.96 (s, 1H), 6.89 (d, *J* = 8.8 Hz, 2H), 3.95 (t, *J* = 5.8 Hz, 2H), 3.81 (s, 3H), 2.91 (t, *J* = 6.2 Hz, 2H), 2.11 – 1.87 (m, 4H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₄H₁₇N₂O 229.1341, found 229.1338. Spectral data match those previously reported.^[5]

2-(4-(tert-butyl)phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4m)



General procedure B was followed using **1m** (125.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4m** in 81% yield (103.0 mg) as a yellow oil: ¹H NMR (600 MHz, Chloroform-*d*) δ 7.89 – 7.49 (m, 2H), 7.44 – 7.31 (m, 2H), 7.02 (s, 1H), 3.97 (t, *J* = 5.9 Hz, 2H), 2.93 (t, *J* = 6.4 Hz, 2H), 2.28 – 1.75 (m, 4H), 1.32 (s, 9H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 149.50, 145.21, 140.66, 131.68, 125.52, 124.58, 113.59, 44.96, 34.62, 31.50, 24.69, 23.19, 21.28.; IR (film) 3409, 2959, 2876, 1911, 1706, 1617, 1557, 1512, 1481, 1426, 1379, 1295, 1267, 1193, 1073, 1037, 948, 864, 825, 761, 670, 509 cm⁻¹; HRMS (ESI-TOF) calcd for ([C₁₇H₂₃N₂]⁺) [M+H]⁺ m/z = 255.1856; found 255.1851.

7-methyl-2-(p-tolyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4n)



General procedure B was followed using 1n (111.1 mg, 0.5 mmol), tert-butyl

carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10 × 10 mm) and platinum plate cathode (10 × 10 × 0.1 mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4n** in 72% yield (81.4 mg) as a yellow solid: (mp 136-138 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 7.72 – 7.53 (m, 2H), 7.15 (d, *J* = 7.9 Hz, 2H), 7.02 (s, 1H), 4.23 – 3.75 (m, 2H), 3.28 – 2.90 (m, 1H), 2.45 (dd, *J* = 16.6, 10.4 Hz, 1H), 2.33 (s, 3H), 2.18 – 1.92 (m, 2H), 1.72 – 1.61 (m, 1H), 1.14 (d, *J* = 6.6 Hz, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 145.27, 140.87, 136.05, 131.65, 129.21, 124.62, 113.27, 43.99, 32.76, 30.93, 28.01, 21.21. IR (film) 2954, 2923, 1707, 1558, 1511, 1480, 1449, 1427, 1373, 1329, 1303, 1269, 1186, 1107, 1072, 909, 824, 763, 727, 646, 547, 509 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₅H₁₉N₂ 227.1548, found 227.1537.

2-(4-ethylphenyl)-6-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (40)



General procedure B was followed using 10 (118.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded 40 in 79% yield (94.9 mg) as a yellow solid:¹H NMR (400 MHz, Chloroform-*d*) δ 7.83 – 7.53 (m, 2H), 7.22 – 7.05 (m, 2H), 6.99 (s, 1H), 4.10 – 3.94 (m, 1H), 3.49 (dd, J = 12.0, 10.2 Hz, 1H), 3.13 – 2.96 (m, 1H), 2.94 – 2.76 (m, 1H), 2.64 (q, J = 7.6 Hz, 2H), 2.17 – 1.95 (m, 2H), 1.65 – 1.51 (m, 1H), 1.24 (t, J = 7.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₆H₂₁N₂ 241.1700, found 241.1693. Spectral data match those previously reported.^[4]

2-(4-methoxyphenyl)-7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4p)



General procedure B was followed using 1p (119.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded 4p in 70% yield (84.8 mg) as a yellow solid (mp 143-145 °C): ¹H NMR (600 MHz, Chloroform-*d*) δ 7.68 – 7.62 (m, 2H), 6.97 (s, 1H), 6.90 – 6.86 (m, 2H), 4.06 – 3.98 (m, 1H), 3.92 – 3.86 (m, 1H), 3.81 (s, 3H), 3.11 – 3.03 (m, 1H), 2.45 (dd, *J* = 16.5, 10.4 Hz, 1H), 2.08 – 1.98 (m, 2H), 1.73 – 1.62 (m, 1H), 1.14

(d, J = 6.6 Hz, 3H). ¹³C NMR (101 MHz, DMSO- d_6) δ 158.61, 145.33, 140.76, 127.40, 126.07, 114.06, 112.76, 55.39, 44.09, 32.81, 31.04, 28.11, 21.29. IR (film) 2963, 1710, 1611, 1556, 1460, 1385, 1365, 1295, 1241, 1171, 1032, 948, 832, 787, 761, 641, 524 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₅H₁₉N₂O 243.1497, found 243.1489.

2-([1,1'-biphenyl]-4-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4q)



General procedure B was followed using 1q (135.1 mg, 0.5 mmol), *tert*-butyl carbazate 2a (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded 4q in 75% yield (102.8 mg) as a yellow solid:¹H NMR (600 MHz, Chloroform-*d*) δ 7.94 – 7.71 (m, 2H), 7.70 – 7.56 (m, 4H), 7.43 (dd, J = 8.3, 7.0 Hz, 2H), 7.37 – 7.29 (m, 1H), 7.11 (s, 1H), 3.99 (t, J = 5.8 Hz, 2H), 2.95 (t, J = 6.2 Hz, 2H), 2.15 – 1.87 (m, 4H). HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₉H₁₉N₂ 275.1548, found 275.1536. Spectral data match those previously reported.^[6]

2-(naphthalen-2-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (4r)



General procedure B was followed using **1r** (122.1 mg, 0.5 mmol), *tert*-butyl carbazate **2a** (330.4 mg 2.5 mmol), ⁿBu₄NBF₄ (0.5 mmol, 164.6 mg), and DMSO (10 mL) added to a three-necked, round-bottomed flask equipped with carbon cloth anode (10×10 mm) and platinum plate cathode ($10 \times 10 \times 0.1$ mm). The constant current (18 mA) electrolysis was carried out at 70 °C under argon for 18 h. Chromatography (DCM/EA = 8/1) afforded **4r** in 86% yield (106.7 mg) as a yellow oil: ¹H NMR (400 MHz, Chloroform-*d*) δ 8.28 (s, 1H), 7.94 – 7.69 (m, 4H), 7.51 – 7.33 (m, 2H), 7.16 (s, 1H), 3.97 (t, *J* = 5.7 Hz, 2H), 2.96 (t, *J* = 6.1 Hz, 2H), 2.05 – 1.89 (m, 4H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 145.58, 140.37, 133.91, 132.51, 131.67, 128.09, 128.05, 127.63, 126.06, 125.24, 123.65, 122.60, 114.49, 44.93, 24.63, 23.03, 21.12. IR (film) 3052, 2947, 2186, 1712, 1628, 1519, 1481, 1424, 1374, 1341, 1318, 1196, 1071, 932, 905, 857, 818, 755, 725, 641, 585, 475 cm⁻¹. HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₇H₁₇N₂ 249.1386, found 249.1380.

2-(naphthalen-2-yl)-3-tosyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (6)



It was obtained in 73% yield (293.8 mg) as a yellow solid (mp 157-159 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.11 (d, J = 1.7 Hz, 1H), 7.95 – 7.80 (m, 3H), 7.75 (dd, J = 8.5, 1.7 Hz, 1H), 7.57 – 7.52 (m, 2H), 7.52 – 7.46 (m, 2H), 7.14 (d, J = 8.1 Hz, 2H), 4.23 (t, J = 6.0 Hz, 2H), 2.96 (t, J = 6.4 Hz, 2H), 2.32 (s, 3H), 2.04 – 1.97 (m, 2H), 1.94 – 1.87 (m, 2H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 148.97, 148.13, 144.25, 139.47, 133.41, 132.89, 130.68, 129.79, 128.67, 127.92, 127.75, 127.18, 127.01, 126.44, 126.08, 123.98, 45.74, 25.28, 22.77, 21.61, 19.79. IR (film) 3055, 2946, 1596, 1506, 1419, 1442, 1316, 1141, 1118, 1080, 964, 894, 825, 810, 762, 694, 655, 586, 539, 475 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₂₄H₂₃N₂O₂S 403.1480, found 403.1476.

3-iodo-2-(naphthalen-2-yl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (7)



It was obtained in 81% yield (181.9 mg) as a yellow solid (mp 152-154 °C): ¹H NMR (400 MHz, Chloroform-*d*) δ 8.45 – 8.33 (m, 1H), 8.09 (dd, J = 8.5, 1.7 Hz, 1H), 7.95 – 7.78 (m, 3H), 7.54 – 7.41 (m, 2H), 3.88 (t, J = 6.0 Hz, 2H), 2.99 (t, J = 6.4 Hz, 2H), 2.11 – 1.94 (m, 4H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 149.06, 142.78, 133.51, 132.75, 131.65, 128.37, 127.81, 127.75, 126.09, 125.96, 125.83, 125.67, 66.84, 46.85, 25.58, 23.44, 21.30. IR (film) 3047, 2925, 1712, 1627, 1496, 1481, 1419, 1358, 1334, 1103, 994, 934, 894, 853, 817, 743, 702, 678, 593, 473 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₁₇H₁₆N₂I 375.0358, found 375.0345.

2-(naphthalen-2-yl)-3-(phenylethynyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine (8)



It was obtained in 78% overall yield (133.8 mg) as a yellow solid (mp 183-185 °C): ¹H

NMR (400 MHz, Chloroform-*d*) δ 8.66 (d, J = 1.7 Hz, 1H), 8.37 (dd, J = 8.6, 1.8 Hz, 1H), 7.89 (dd, J = 8.8, 3.6 Hz, 2H), 7.85 – 7.79 (m, 1H), 7.61 – 7.53 (m, 2H), 7.51 – 7.33 (m, 5H), 4.07 (t, J = 5.9 Hz, 2H), 2.99 (t, J = 6.3 Hz, 2H), 2.20 – 1.85 (m, 4H). ¹³C NMR (151 MHz, Chloroform-*d*) δ 146.31, 143.55, 133.77, 132.89, 131.63, 131.18, 128.68, 128.56, 128.43, 127.97, 127.76, 126.09, 125.73, 124.64, 124.49, 123.20, 110.82, 98.79, 79.88, 43.67, 25.07, 22.79, 20.85. IR (film) 3444, 3343, 3054, 2947, 2198, 1956, 1669, 1519, 1442, 1389, 1234, 1191, 1092, 964, 910, 817, 749, 689, 647, 586, 564, 484 cm⁻¹; HRMS (ESI-TOF) m/z [M + H]⁺ Calcd for C₂₅H₂₁N₂ 349.1699, found 349.1696.

10.References

- [1] W. Kim, H. Y. Kim, K. Oh, J Org Chem 2021, 86, 15973-15991.
- [2] D. V. Patil, Y. Lee, H. Y. Kim, K. Oh, Org Lett 2022, 24, 5840-5844.
- [3] P.-O. Delaye, M. Pénichon, H. Allouchi, C. Enguehard-Gueiffier, A. Gueiffier, Org Biomol Chem 2017, 15, 4199-4204.
- [4] J. Wen, H. Qin, K. Yan, X. Yang, X. Sun, W. Wei, J. Yang, H. Wang, Org Lett 2020, 22, 8824-8828.
- [5] Q. Xuan, Q. Song, Org Lett **2016**, 18, 4250-4253.
- [6] J. Li, P. Zhang, M. Jiang, H. Yang, Y. Zhao, H. Fu, Org Lett 2017, 19, 1994-1997.

11. Copies of 1H NMR, 13C NMR and 19F NMR

3a



3e

3f

3j

3m

30

4a

4d

4f

4j

4m

4n

4p

4q

4r

6

